On May 12, 2025, President Trump signed Executive Order 14297, implementing a Most-Favored-Nation pricing model for prescription drugs covered under Medicare. The executive order directs the federal government to negotiate drug prices based on the lowest amounts paid for the same medications in other developed nations, effectively establishing an international price benchmark that Medicare reimbursements cannot exceed. This represents a significant shift in pharmaceutical policy, as it grants the federal government explicit authority to use foreign pricing data as a negotiating tool against domestic drug manufacturers.

The policy directly affects millions of Medicare beneficiaries and the federal government's drug spending. Seniors and disabled Americans enrolled in Medicare would see potential reductions in their out-of-pocket costs for prescription medications, while the government aims to reduce its overall pharmaceutical expenditures. However, the impact depends heavily on implementation specifics—which drugs are covered, how prices are negotiated, and what enforcement mechanisms exist. Pharmaceutical manufacturers face pressure to lower domestic prices or risk reduced Medicare reimbursement, fundamentally altering their pricing strategies for the American market.

This action stands in stark contrast to the broader Trump administration healthcare trajectory evident in related policies from 2025 and 2026. While this executive order attempts to reduce drug costs through government negotiation, other simultaneous healthcare actions have systematically restricted access to medications and preventive services. The FDA's authorization of fruit-flavored vapes, the federal court restriction on mifepristone telehealth access, the administration's vaccine recommendation rollbacks, and the Title X program's shift away from birth control represent a pattern of healthcare deregulation paired with reduced access to specific medications and treatments. The MFN drug pricing order appears as an outlier within an administration that has otherwise prioritized pharmaceutical industry interests and restricted government intervention in medication access.

The legal status of this executive order remains subject to pharmaceutical industry challenge. Drug manufacturers have historically opposed price controls, arguing they discourage innovation and research investment. Courts may evaluate whether the executive order exceeds presidential authority under existing statutory frameworks or whether congressional approval is required for such sweeping pricing mechanisms. Congressional Democrats have generally supported drug price negotiation efforts, though the implementation details will determine whether this executive order aligns with or diverges from legislative proposals.